This page contains affiliate links. We may earn a commission at no extra cost to you.

$15–$30 for a 60-day supply

Check Price on Amazon
Evidence: Moderate-Strong — multiple European RCTs show significant reduction in neuropathic symptom scores in diabetic neuropathy. One RCT specifically showed benefit at 300 mg/day over 6 weeks. Widely used clinically in Europe for diabetic neuropathy.

Benfotiamine is a synthetic, fat-soluble derivative of thiamine (vitamin B1) that penetrates nerve cell membranes far more effectively than standard water-soluble thiamine supplements. Thiamine deficiency is a well-established cause of peripheral neuropathy, and elevated blood sugar — even in the pre-diabetic range — impairs thiamine metabolism in nerve tissue. Benfotiamine specifically activates transketolase, a key enzyme in glucose metabolism, reducing the accumulation of toxic glucose metabolites that damage nerve fibers and blood vessels in diabetic and pre-diabetic neuropathy. Multiple clinical trials, primarily European, support its use for reducing neuropathic symptoms in diabetic patients, and it is widely recommended by integrative medicine practitioners as a cornerstone of nutritional support for peripheral nerve health.

How It Works

Standard thiamine HCl (the form in most B-complex vitamins) is water-soluble and has limited ability to enter nerve cell lipid membranes. Benfotiamine’s fat-soluble structure allows it to penetrate these membranes and reach the intracellular compartment, where it is converted to active thiamine pyrophosphate. This active form powers transketolase, the enzyme that shunts excess intracellular glucose into the non-harmful pentose phosphate pathway rather than through the damaging advanced glycation end-product (AGE) and polyol pathways.

By blocking these damaging glucose metabolism pathways, benfotiamine reduces the formation of AGEs — proteins crosslinked with excess glucose — which stiffen nerve blood vessels, reduce blood flow, and directly damage nerve fibers. Studies have shown benfotiamine can reduce markers of AGE formation in nerve tissue by up to 70 percent, a more potent effect than standard water-soluble thiamine. Additionally, benfotiamine reduces NF-kappaB activation — a central inflammatory signaling pathway implicated in many types of nerve damage.

What the Research Says

The most cited clinical trial of benfotiamine for diabetic neuropathy is a 2008 RCT published in Experimental and Clinical Endocrinology & Diabetes, which found that 300 mg per day of benfotiamine for 6 weeks significantly reduced neuropathic symptom scores (specifically pain, burning, and paresthesias) compared to placebo. A separate trial found that a combination of benfotiamine and other B vitamins produced greater improvements in nerve conduction velocity than standard water-soluble B vitamins.

Basic science research adds mechanistic support: animal models of diabetic neuropathy show that benfotiamine prevents the structural nerve damage associated with hyperglycemia. Human studies have found that benfotiamine reduces plasma levels of AGEs and homocysteine — both of which are associated with nerve damage. Benfotiamine is particularly relevant for patients taking metformin, which depletes thiamine (and vitamin B12) as a secondary effect of long-term use.

Evidence for benfotiamine in non-diabetic neuropathy is sparse, though its mechanism — reducing glucose-mediated nerve toxicity — is relevant to any patient with pre-diabetes or metabolic syndrome contributing to nerve damage.

Benfotiamine vs. Regular Thiamine

Standard thiamine HCl found in most B-complex vitamins achieves relatively low intracellular concentrations even at high oral doses because of its water solubility and active transport saturation. Benfotiamine’s bioavailability in nerve tissue has been measured at approximately five times higher than standard thiamine at equivalent oral doses. This pharmacokinetic advantage is the primary rationale for preferring benfotiamine over standard thiamine for neuropathy applications.

For patients concerned about thiamine deficiency from alcohol use disorder, standard IV or high-dose oral thiamine remains the standard of care for Wernicke’s encephalopathy prevention. Benfotiamine is best suited for the metabolic/neuroprotective use case in patients with diabetes, pre-diabetes, or established peripheral neuropathy rather than for acute thiamine repletion in deficiency states.

Safety and Drug Interactions

Benfotiamine has an excellent safety profile across clinical trials. No serious adverse effects have been reported at doses up to 600 mg per day. Unlike standard thiamine, which may rarely cause allergic reactions when administered intravenously, oral benfotiamine is well tolerated by the vast majority of users. There are no established drug interactions, though informing your physician and pharmacist of all supplements remains important.

Benfotiamine does not cause the same concern as excess vitamin B6, which can cause toxic neuropathy at high doses — benfotiamine has no established toxic upper limit in clinical use. Because it is a fat-soluble compound, it can be taken with or without food, unlike some water-soluble B vitamins whose absorption is more consistently good on an empty stomach.

Pros

• Significantly higher intracellular bioavailability than standard thiamine supplements
• Addresses specific glucose-metabolism pathways underlying diabetic nerve damage
• Well-tolerated with an excellent safety profile in clinical trials
• Particularly valuable for metformin users who may have depleted thiamine
• Can be taken with or without food

Cons

• Primary evidence base is in diabetic neuropathy — less applicable to non-metabolic neuropathy types
• More expensive than standard thiamine HCl supplements
• Evidence base smaller than for alpha lipoic acid — fewer total RCTs

Frequently Asked Questions

Is benfotiamine the same as regular vitamin B1?

No — benfotiamine is a fat-soluble derivative of thiamine (B1) with substantially higher bioavailability in nerve tissue. Standard thiamine (thiamine HCl or thiamine mononitrate) in B-complex vitamins is water-soluble and reaches much lower intracellular concentrations. For neuropathy support, benfotiamine is preferable to standard thiamine supplements.

Can benfotiamine be combined with alpha lipoic acid?

Yes, and this combination is commonly used in integrative neuropathy protocols. Both supplements work through complementary mechanisms — benfotiamine targeting advanced glycation and the polyol pathway, ALA targeting oxidative stress and mitochondrial function. Several combination products include both, and there are no known interactions or safety concerns with co-administration.

How long should I take benfotiamine before deciding if it works?

Clinical trials have measured outcomes at 6 weeks to 3 months. A minimum 8-week consistent trial at an appropriate dose is reasonable before evaluating response. Some patients report early symptom changes within 3 to 4 weeks, while others notice gradual improvement over several months. Keep a simple pain diary to track changes rather than relying on memory.

Buy on Amazon — $15–$30 for a 60-day supply